VAL-339851
Phase 1Completed 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza
Trial Timeline
May 11, 2016 → Aug 13, 2018
NCT ID
NCT03345043About VAL-339851
VAL-339851 is a phase 1 stage product being developed by Moderna for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT03345043. Target conditions include Influenza.
What happened to similar drugs?
20 of 20 similar drugs in Influenza were approved
Approved (20) Terminated (1) Active (0)
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03345043 | Phase 1 | Completed |
Competing Products
20 competing products in Influenza
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1010 | Moderna | Phase 2 | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1011.1 | Moderna | Phase 2 | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1073 | Moderna | Phase 2 | 0 |
| VAL-506440 | Moderna | Phase 1 | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1083 | Moderna | Phase 2 | 0 |
| mRNA-1010 | Moderna | Phase 3 | 0 |
| mRNA-1018-H5 | Moderna | Phase 3 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1030 | Moderna | Phase 2 | 0 |
| mRNA-1018 for H5N8 | Moderna | Phase 2 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1010 | Moderna | Phase 2 | 0 |